Top

Journal of Inflammation

Published in:

Open Access 01-12-2020 | Research

Prediction and identification of novel HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from endocan

Authors: Gaohai Shao, Qingjun Liu, Ling Yang, Guibo Feng, Wang Zhao, Zhongyan Huang, Zhao Yang

Published in: Journal of Inflammation | Issue 1/2020

Abstract

Background

Prediction and identification of cytotoxic T lymphocyte (CTL) epitopes from tumor associated antigens is a crucial step for the development of tumor immunotherapy strategy. Endocan has been identified as antigen overexpressed in various tumors.

Methods

In this experiment, we predicted and identified HLA-A2-restricted CTL epitopes from endocan by using the following procedures. Firstly, we predicted the epitopes from the amino acid sequence of endocan by computer-based methods; Secondly, we determined the affinity of the predicted peptide with HLA-A2.1 molecule by peptide-binding assay; Thirdly, we elicited the primary T cell response against the predicted peptides in vitro; Lastly, we tested the specific CTLs toward endocan and HLA-A2.1 positive target cells.

Results

These data demonstrated that peptides of endocan containing residues 4–12 and 9–17 could elicit specific CTLs producing interferon-γ and cytotoxicity.

Conclusions

Therefore, our findings suggested that the predicted peptides were novel HLA-A2.1-restricted CTL epitopes, and might provide promising target for tumor immunotherapy.

Lam FC, Morton SW, Wyckoff J, Vu Han TL, Hwang MK, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 2018;9:1991.PubMedPubMedCentralCrossRef

Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018;360:331–5.PubMedPubMedCentralCrossRef

Komori T, Muragaki Y, Chernov MF. Pathology and genetics of Gliomas. Prog Neurol Surg. 2018;31:1–37.PubMedCrossRef

Wong ET, Lok E, Swanson KD. Alternating electric fields therapy for malignant Gliomas: from bench observation to clinical reality. Prog Neurol Surg. 2018;32:180–95.PubMedCrossRef

Paldor I, Chaichana KL, Brem H, Tyler BM. Targeted local therapy for Management of Intracranial High-Grade Gliomas. Prog Neurol Surg. 2018;32:159–71.PubMedCrossRef

Parker Kerrigan BC, Hossain A, Yamashita S, Lang FF. Stem cell therapy of Gliomas. Prog Neurol Surg. 2018;32:124–51.PubMedCrossRef

Qiu CR, Fu Q, Sui J, Zhang Q, Wei P, et al. Endocan: endothelial dysfunction, inflammation, or both? Angiology. 2017;68:80.PubMedCrossRef

Emet S, Elitok A, Onur I, Kocaaga M, Bilge AK, et al. Endocan: a novel biomarker associated with well-developed coronary collateral circulation in patients with stable angina and chronic total occlusion. J Thromb Thrombolysis. 2017;43:60–7.PubMedCrossRef

Sumei Z, Shaolong C, Xiang W, Yinliang Q, Qing Z, et al. Endocan reduces the malign grade of gastric cancer cells by regulating associated protein expression. Tumour Biol. 2016;37:14915–21.PubMedCrossRef

10.

Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, et al. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 2012;22:757–64.PubMedPubMedCentralCrossRef

11.

Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, et al. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res. 2013;73:1097–106.PubMedCrossRef

12.

Sagara A, Igarashi K, Otsuka M, Kodama A, Yamashita M, et al. Endocan as a prognostic biomarker of triple-negative breast cancer. Breast Cancer Res Treat. 2017;161:269–78.PubMedCrossRef

13.

Huang X, Chen C, Wang X, Zhang JY, Ren BH, et al. Prognostic value of endocan expression in cancers: evidence from meta-analysis. Onco Targets Ther. 2016;9:6297–304.PubMedPubMedCentralCrossRef

14.

Yang J, Sheng S, Yang Q, Li L, Qin S, et al. Endocan silencing induces programmed cell death in hepatocarcinoma. Oncol Lett. 2017;14:5333–9.PubMedPubMedCentral

15.

Mertoglu C, Gunay M, Yerligok O. Could Endocan, a marker of inflammation and endothelial dysfunction, be a new diagnostic marker for fibromyalgia? Clin Lab. 2018;64:405–10.PubMedCrossRef

16.

Gaudet A, Portier L, Prin M, Copin MC, Tsicopoulos A, et al. (2019) Endocan regulates acute lung inflammation through control of leukocyte diapedesis. J Appl Physiol. 1985;127:668–78.CrossRef

17.

Liu H, Chen L, Liu J, Meng H, Zhang R, et al. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett. 2017;411:182–90.PubMedCrossRef

18.

Saito H, Kitagawa K, Yoneda T, Fukui Y, Fujsawa M, et al. Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro. Cancer Gene Ther. 2017;24:289–96.PubMedCrossRef

19.

Choi CW, Jeong MH, Park YS, Son CH, Lee HR, et al. Combination treatment of stereotactic body radiation therapy and immature dendritic cell vaccination for augmentation of local and systemic effects. Cancer Res Treat. 2018.

20.

Lanterna C, Musumeci A, Raccosta L, Corna G, Moresco M, et al. The administration of drugs inhibiting cholesterol/oxysterol synthesis is safe and increases the efficacy of immunotherapeutic regimens in tumor-bearing mice. Cancer Immunol Immunother. 2016;65:1303–15.PubMedCrossRef

21.

Jo J, Wen PY. Antiangiogenic therapy of high-grade Gliomas. Prog Neurol Surg. 2018;31:180–99.PubMed

22.

Wesseling P, Capper D. WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol. 2018;44:139–50.PubMedCrossRef

23.

Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat Med. 2018;24:572–9.PubMedPubMedCentralCrossRef

24.

Zhou Y, Tan Z, Chen K, Wu W, Zhu J, et al. Overexpression of SHCBP1 promotes migration and invasion in gliomas by activating the NF-kappaB signaling pathway. Mol Carcinog. 2018;57:1181–90.PubMedCrossRef

25.

Ishikawa E, Muragaki Y, Yamamoto T, Ohno T, Matsumura A. Vaccine therapy of high-grade Gliomas. Prog Neurol Surg. 2018;32:101–11.PubMedCrossRef

26.

Iwami K, Natsume A, Wakabayashi T. Cytokine therapy of Gliomas. Prog Neurol Surg. 2018;32:79–89.PubMedCrossRef

27.

Butowski N. Novel and prospective molecular targets for therapy of intracranial Gliomas. Prog Neurol Surg. 2018;32:66–78.PubMedCrossRef

28.

Ciaglia E, Laezza C, Abate M, Pisanti S, Ranieri R, et al. Recognition by natural killer cells of N6-isopentenyladenosine-treated human glioma cell lines. Int J Cancer. 2018;142:176–90.PubMedCrossRef

29.

Zhu C, Chrifi I, Mustafa D, van der Weiden M, Leenen PJM, et al. CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma. Oncogene. 2017;36:5356–68.PubMedPubMedCentralCrossRef

30.

Wildes TJ, Grippin A, Dyson KA, Wummer BM, Damiani DJ, et al. Cross-talk between T cells and hematopoietic stem cells during adoptive cellular therapy for malignant Glioma. Clin Cancer Res. 2018;24:3955–66.PubMedPubMedCentralCrossRef

31.

Baker GJ, Chockley P, Zamler D, Castro MG, Lowenstein PR. Natural killer cells require monocytic gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. Oncoimmunology. 2016;5:e1163461.PubMedPubMedCentralCrossRef

32.

Chitadze G, Lettau M, Luecke S, Wang T, Janssen O, et al. NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human gammadelta T cells: modulation by temozolomide and a disintegrin and metalloproteases 10 and 17 inhibitors. Oncoimmunology. 2016;5:e1093276.PubMedCrossRef

33.

Orozco-Morales M, Sanchez-Garcia FJ, Golan-Cancela I, Hernandez-Pedro N, Costoya JA, et al. RB mutation and RAS overexpression induce resistance to NK cell-mediated cytotoxicity in glioma cells. Cancer Cell Int. 2015;15:57.PubMedPubMedCentralCrossRef

34.

Qin K, Tian G, Li P, Chen Q, Zhang R, et al. Anti-glioma response of autologous T cells stimulated by autologous dendritic cells electrofused with CD133+ or CD133- glioma cells. J Neuroimmunol. 2012;242:9–15.PubMedCrossRef

35.

Chen H, Yuan B, Zheng Z, Liu Z, Wang S, et al. A novel vaccine containing EphA2 epitope and LIGHT plasmid induces robust cellular immunity against glioma U251 cells. Cell Immunol. 2011;272:102–6.PubMedCrossRef

36.

Adach-Kilon A, Swiatek-Machado K, Kaminska B, Dabrowski M. Signal transducer and activator of transcription 1 (Stat1) maintains basal mRNA expression of pro-survival stat3-target genes in glioma C6 cells. J Cell Biochem. 2011;112:3685–94.PubMedCrossRef

37.

Liu Z, Poiret T, Persson O, Meng Q, Rane L, et al. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma. Cancer Immunol Immunother. 2018;67:237–46.PubMedCrossRef

38.

Liu Y, Yuelling LW, Wang Y, Du F, Gordon RE, et al. Astrocytes promote Medulloblastoma progression through hedgehog secretion. Cancer Res. 2017;77:6692–703.PubMedPubMedCentralCrossRef

39.

Liu H, Smith AJ, Ball SS, Bao Y, Bowater RP, et al. Sulforaphane promotes ER stress, autophagy, and cell death: implications for cataract surgery. J Mol Med (Berl). 2017;95:553–64.CrossRef

40.

van Kooyk Y, Unger WW, Fehres CM, Kalay H, Garcia-Vallejo JJ. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol Immunol. 2013;55:143–5.PubMedCrossRef

41.

Eleveld-Trancikova D, Sanecka A, van Hout-Kuijer MA, Looman MW, Hendriks IA, et al. DC-STAMP interacts with ER-resident transcription factor LUMAN which becomes activated during DC maturation. Mol Immunol. 2010;47:1963–73.PubMedCrossRef

42.

Weng D, Calderwood SK, Gong J. A novel heat shock protein 70-based vaccine prepared from DC-tumor fusion cells. Methods Mol Biol. 2018;1709:359–69.PubMedCrossRef

43.

Turer CC, Durmus D, Balli U, Guven B. Effect of non-surgical periodontal treatment on gingival Crevicular fluid and serum Endocan, vascular endothelial growth factor-a, and tumor necrosis factor-alpha levels. J Periodontol. 2017;88:493–501.PubMedCrossRef

44.

Yassine H, De Freitas CN, Depontieu F, Scherpereel A, Awad A, et al. The non glycanated endocan polypeptide slows tumor growth by inducing stromal inflammatory reaction. Oncotarget. 2015;6:2725–35.PubMedCrossRef

45.

Abid MR, Yi X, Yano K, Shih SC, Aird WC. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res. 2006;72:136–45.PubMedCrossRef

46.

Kali A, Shetty KS. Endocan: a novel circulating proteoglycan. Indian J Pharmacol. 2014;46:579–83.PubMedPubMedCentralCrossRef

47.

Yu PH, Chou SF, Chen CL, Hung H, Lai CY, et al. Upregulation of endocan by Epstein-Barr virus latent membrane protein 1 and its clinical significance in nasopharyngeal carcinoma. PLoS One. 2013;8:e82254.PubMedPubMedCentralCrossRef

48.

Matano F, Yoshida D, Ishii Y, Tahara S, Teramoto A, et al. Endocan, a new invasion and angiogenesis marker of pituitary adenomas. J Neuro-Oncol. 2014;117:485–91.CrossRef

49.

Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res. 2006;12:4575–82.PubMedCrossRef

50.

Delehedde M, Devenyns L, Maurage CA, Vives RR. Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol. 2013;2013:705027.PubMedPubMedCentralCrossRef

Title: Prediction and identification of novel HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from endocan
Authors: Gaohai Shao
Qingjun Liu
Ling Yang
Guibo Feng
Wang Zhao
Zhongyan Huang
Zhao Yang
Publication date: 01-12-2020
Publisher: BioMed Central
Published in: Journal of Inflammation / Issue 1/2020
Electronic ISSN: 1476-9255
DOI: https://doi.org/10.1186/s12950-020-00240-w

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prediction and identification of novel HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from endocan

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Circular RNA-CDR1as acts as the sponge of microRNA-641 to promote osteoarthritis progression

Urolithin a attenuates IL-1β-induced inflammatory responses and cartilage degradation via inhibiting the MAPK/NF-κB signaling pathways in rat articular chondrocytes

Corpus cavernosum smooth muscle cell dysfunction and phenotype transformation are related to erectile dysfunction in prostatitis rats with chronic prostatitis/chronic pelvic pain syndrome

LncRNA THRIL is upregulated in sepsis and sponges miR-19a to upregulate TNF-α in human bronchial epithelial cells

A novel sphingosylphosphorylcholine and sphingosine-1-phosphate receptor 1 antagonist, KRO-105714, for alleviating atopic dermatitis

Offspring sex affects the susceptibility to maternal smoking-induced lung inflammation and the effect of maternal antioxidant supplementation in mice

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page